Lucier selected for three 2026 scientific and accelerator programs
Lucier was selected for the SCCM Discovery Critical Care Innovation Incubator, ACC.26 Scientific Session, and Nucleate Activator's Texas program.
Company announcement from Lucier Pharmaceuticals.
Lucier Pharmaceuticals was selected to participate in three prominent scientific and company-building programs scheduled for 2026.
The company's coronary arteriolar constriction research was accepted for presentation at the Society of Critical Care Medicine's Discovery Critical Care Innovation Incubator in Chicago and at the American College of Cardiology's ACC.26 Scientific Session in New Orleans.
Lucier was also selected as a finalist in the Texas chapter of the Nucleate Activator 2026 program. The six-month program connects participating teams with mentorship, professional resources, and a broader bio-innovation network. Founder and CEO Dr. Guangrong Lu was selected to represent the company through the scientific presentations and accelerator pitch.
Together, these selections recognize both the scientific foundation of Lucier's programs and the company's continued progress toward translating its research into potential therapies for coronary microvascular dysfunction.
Lucier's product candidates are investigational and in preclinical development. They have not been approved for patient use.